TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Valsartan in Elderly Isolated Systolic Hypertension
Brief Summary: The aim of this study is to compare the incidence of cardiovascular events between two target systolic blood pressure levels, below 140 mmHg and below 150 mmHg under treatment with valsartan in elderly isolated systolic hypertensive patients in Japan.


Options:
A: Arm Label: Benazepril/amlodipine; Type: EXPERIMENTAL; Interventions: Drug: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1, Drug: Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2, Drug: Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter | Arm Label: Benazepril/hydrochlorothiazide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1, Drug: Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2, Drug: Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter | Intervention Type: DRUG; Name: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1; Assigned to Arm(s): Benazepril/amlodipine | Intervention Type: DRUG; Name: Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2; Assigned to Arm(s): Benazepril/amlodipine | Intervention Type: DRUG; Name: Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter; Assigned to Arm(s): Benazepril/amlodipine | Intervention Type: DRUG; Name: Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1; Assigned to Arm(s): Benazepril/hydrochlorothiazide | Intervention Type: DRUG; Name: Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2; Assigned to Arm(s): Benazepril/hydrochlorothiazide | Intervention Type: DRUG; Name: Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter; Assigned to Arm(s): Benazepril/hydrochlorothiazide
B: Arm Label: Intensive BP control; Type: EXPERIMENTAL; Interventions: Drug: Intensive BP control | Arm Label: Standard BP control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard BP control | Intervention Type: DRUG; Name: Intensive BP control; Assigned to Arm(s): Intensive BP control | Intervention Type: DRUG; Name: Standard BP control; Assigned to Arm(s): Standard BP control
C: Arm Label: Intensive Control of SBP; Type: EXPERIMENTAL; Interventions: Drug: Intensive control of SBP | Arm Label: Standard Control of SBP; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard control of SBP | Intervention Type: DRUG; Name: Intensive control of SBP; Assigned to Arm(s): Intensive Control of SBP | Intervention Type: DRUG; Name: Standard control of SBP; Assigned to Arm(s): Standard Control of SBP
D: Arm Label: strict control; Type: ACTIVE_COMPARATOR; Interventions: Other: target blood pressure | Arm Label: moderate control; Type: ACTIVE_COMPARATOR; Interventions: Other: target blood pressure | Intervention Type: OTHER; Name: target blood pressure; Assigned to Arm(s): moderate control, strict control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Combination Therapy With Lifestyle Intervention and Metformin in Females With Polycystic Ovary Syndrome
Brief Summary: The purpose of this study is to determine if the combination therapy of lifestyle intervention and use of Metformin together will improve ovulation induction and hyperandrogenemia in women with polycystic ovary syndrome, by gathering data from adult and adolescent females.


Options:
A: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Behavioral: Lifestyle Intervention | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Lifestyle Intervention | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Metformin, Placebo
C: Arm Label: metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin | Arm Label: liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: liraglutide | Arm Label: metformin and liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin and liraglutide | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): metformin | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): liraglutide | Intervention Type: DRUG; Name: metformin and liraglutide; Assigned to Arm(s): metformin and liraglutide
D: Arm Label: BMI > 32; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Drug: Placebo | Arm Label: BMI </= 32; Type: EXPERIMENTAL; Interventions: Drug: Metformin + Clomiphene, Drug: Metformin, Drug: Clomiphene | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): BMI > 32 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BMI > 32 | Intervention Type: DRUG; Name: Metformin + Clomiphene; Assigned to Arm(s): BMI </= 32 | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): BMI </= 32 | Intervention Type: DRUG; Name: Clomiphene; Assigned to Arm(s): BMI </= 32

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Combination Therapy With Lifestyle Intervention and Metformin in Females With Polycystic Ovary Syndrome
Brief Summary: The purpose of this study is to determine if the combination therapy of lifestyle intervention and use of Metformin together will improve ovulation induction and hyperandrogenemia in women with polycystic ovary syndrome, by gathering data from adult and adolescent females.


Options:
A: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Behavioral: Lifestyle Intervention | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Lifestyle Intervention | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Metformin, Placebo
B: Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Simvastatin and Metformin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): N/A
C: Arm Label: 3 mg drospirenone and 20 µg ethinyl-estradiol; Type: ACTIVE_COMPARATOR; Interventions: Drug: 3 mg drospirenone and 20 µg ethinyl-estradiol | Arm Label: 3 mg drospirenone and 30 µg ethinyl-estradiol; Type: ACTIVE_COMPARATOR; Interventions: Drug: 3 mg drospirenone and 30 µg ethinyl-estradiol | Intervention Type: DRUG; Name: 3 mg drospirenone and 20 µg ethinyl-estradiol; Assigned to Arm(s): 3 mg drospirenone and 20 µg ethinyl-estradiol | Intervention Type: DRUG; Name: 3 mg drospirenone and 30 µg ethinyl-estradiol; Assigned to Arm(s): 3 mg drospirenone and 30 µg ethinyl-estradiol
D: Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Metformin plus spironolactone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin plus Spironolactone | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Metformin plus Spironolactone; Assigned to Arm(s): Metformin plus spironolactone

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Combination Therapy With Lifestyle Intervention and Metformin in Females With Polycystic Ovary Syndrome
Brief Summary: The purpose of this study is to determine if the combination therapy of lifestyle intervention and use of Metformin together will improve ovulation induction and hyperandrogenemia in women with polycystic ovary syndrome, by gathering data from adult and adolescent females.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desorelle | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Drug: Desorelle | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Desorelle; Assigned to Arm(s): 2, 3
B: Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ethynyl-estradiol plus cyproterone acetate; Assigned to Arm(s): N/A
C: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Behavioral: Lifestyle Intervention | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Lifestyle Intervention | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Metformin, Placebo
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Six-Month, Double-Blind, Placebo Controlled, Durability of Effect Study of Pregabalin for Pain Associated With Fibromyalgia
Brief Summary: The purpose of this research study of pregabalin and fibromyalgia is to see if 1. pregabalin reduces the pain of fibromyalgia and if this effect lasts for six months and 2. to see if different dosages work better (reduce pain and mild to no side effects) for different people.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): 1
B: Arm Label: Lyrica; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Lyrica | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Flexible Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin | Arm Label: Fixed Dosing; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Fixed Dosing, Flexible Dose
D: Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Long-Term, Open-Label, Safety Trial of Pregabalin in Patients With Fibromyalgia
Brief Summary: The main purpose of this protocol is to evaluate the long-term safety of pregabalin in patients who participated in the previous fibromyalgia Study A0081056 and who wish to receive open-label pregabalin therapy.


Options:
A: Arm Label: Pregabalin; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): 1
D: Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing ICU Related Anxiety Through a Structured Information Program. A Randomized Controlled Clinical Trial
Brief Summary: According to current evidence and psychological theorizing, the provision of information seems to be a promising way to reduce the anxiety of patients that is related to their scheduled ICU stay. An ICU-specific information program will be investigated in a randomized controlled clinical trial involving 120 patients undergoing elective open heart surgery and 20 patients undergoing abdominal surgery. It is expected that the patients in the test group will experience less anxiety and ICU related discomfort than patients in the control group.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Structured information | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Other: Unspecific conversation | Intervention Type: BEHAVIORAL; Name: Structured information; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Unspecific conversation; Assigned to Arm(s): 2
B: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: ICU-specific information program | Intervention Type: BEHAVIORAL; Name: ICU-specific information program; Assigned to Arm(s): Intervention group
C: Arm Label: Intensive Communication; Type: EXPERIMENTAL; Interventions: Other: Intensive Communication System | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Intensive Communication System; Assigned to Arm(s): Intensive Communication
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Facilitator-Based intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Facilitator-Based intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Two Protocols to Prevent the Acquisition of Methicillin-Resistant Staphylococcus Aureus in Intensive Care Units.
Brief Summary: Nosocomial infections is a major problem in intensive care units due to both growing incidence and pathogens implicated which become increasingly resistant to antibiotics. According to the Center for Disease Control (USA), Staphylococcus aureus is responsible for approximately 10% of cases. In Europe, 79% of the S.aureus strains are resistant to methicillin, a routinely used antibiotic. Recommendations for the prevention of transmission of these resistant bacteria are rarely based on controlled trials. Therefore the aim of our study is to evaluate two protocols to prevent the acquisition of methicillin-resistant S. Aureus in intensive care units: either a reinforced isolation precautions protocol or a standard precautions protocol.


Options:
A: Arm Label: White coat group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Uniform group; Type: EXPERIMENTAL; Interventions: Other: Physician uniform | Intervention Type: OTHER; Name: Physician uniform; Assigned to Arm(s): Uniform group
B: Intervention Type: PROCEDURE; Name: Reinforced isolation + Muciprocine; Assigned to Arm(s): N/A
C: Arm Label: Hand hygiene; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Hand hygiene plus gloving; Type: EXPERIMENTAL; Interventions: Other: Gloves | Intervention Type: OTHER; Name: Gloves; Assigned to Arm(s): Hand hygiene plus gloving
D: Intervention Type: PROCEDURE; Name: Bathing with Chlorhexidine Impregnated Washcloths; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Two Protocols to Prevent the Acquisition of Methicillin-Resistant Staphylococcus Aureus in Intensive Care Units.
Brief Summary: Nosocomial infections is a major problem in intensive care units due to both growing incidence and pathogens implicated which become increasingly resistant to antibiotics. According to the Center for Disease Control (USA), Staphylococcus aureus is responsible for approximately 10% of cases. In Europe, 79% of the S.aureus strains are resistant to methicillin, a routinely used antibiotic. Recommendations for the prevention of transmission of these resistant bacteria are rarely based on controlled trials. Therefore the aim of our study is to evaluate two protocols to prevent the acquisition of methicillin-resistant S. Aureus in intensive care units: either a reinforced isolation precautions protocol or a standard precautions protocol.


Options:
A: Intervention Type: PROCEDURE; Name: Reinforced isolation + Muciprocine; Assigned to Arm(s): N/A
B: Arm Label: Arm 1: Usual Care-Active Surveillance; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Arm 2: Targeted Decolonization; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine bath and nasal mupirocin | Arm Label: Arm 3: Universal Decolonization; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine bath and nasal mupirocin | Intervention Type: DRUG; Name: Chlorhexidine bath and nasal mupirocin; Assigned to Arm(s): Arm 2: Targeted Decolonization, Arm 3: Universal Decolonization
C: Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine oral care (CHX-Oro), Drug: Selective oropharyngeal decontamination (SOD), Drug: Selective Digestive Decontamination (SDD) | Arm Label: Chlorhexidine oral care (CHX-Oro); Type: EXPERIMENTAL; Interventions: Drug: Chlorhexidine oral care (CHX-Oro) | Arm Label: Selective oropharyngeal decontamination; Type: EXPERIMENTAL; Interventions: Drug: Selective oropharyngeal decontamination (SOD) | Arm Label: Selective digestive decontamination; Type: EXPERIMENTAL; Interventions: Drug: Selective Digestive Decontamination (SDD) | Intervention Type: DRUG; Name: Chlorhexidine oral care (CHX-Oro); Assigned to Arm(s): Chlorhexidine oral care (CHX-Oro), Standard care | Intervention Type: DRUG; Name: Selective oropharyngeal decontamination (SOD); Assigned to Arm(s): Selective oropharyngeal decontamination, Standard care | Intervention Type: DRUG; Name: Selective Digestive Decontamination (SDD); Assigned to Arm(s): Selective digestive decontamination, Standard care
D: Arm Label: residual gastric volume; Type: OTHER; Interventions: Procedure: monitoring of residual gastric volume | Arm Label: residual gastric volume not monitored; Type: OTHER; Interventions: Procedure: not monitoring of residual gastric volume | Intervention Type: PROCEDURE; Name: monitoring of residual gastric volume; Assigned to Arm(s): residual gastric volume | Intervention Type: PROCEDURE; Name: not monitoring of residual gastric volume; Assigned to Arm(s): residual gastric volume not monitored

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Two Protocols to Prevent the Acquisition of Methicillin-Resistant Staphylococcus Aureus in Intensive Care Units.
Brief Summary: Nosocomial infections is a major problem in intensive care units due to both growing incidence and pathogens implicated which become increasingly resistant to antibiotics. According to the Center for Disease Control (USA), Staphylococcus aureus is responsible for approximately 10% of cases. In Europe, 79% of the S.aureus strains are resistant to methicillin, a routinely used antibiotic. Recommendations for the prevention of transmission of these resistant bacteria are rarely based on controlled trials. Therefore the aim of our study is to evaluate two protocols to prevent the acquisition of methicillin-resistant S. Aureus in intensive care units: either a reinforced isolation precautions protocol or a standard precautions protocol.


Options:
A: Arm Label: Chlorhexidine bathing; Type: EXPERIMENTAL; Interventions: Other: Chlorhexidine bathing | Arm Label: Non-chlorhexidine bathing; Type: ACTIVE_COMPARATOR; Interventions: Other: Non-chlorhexidine bathing | Intervention Type: OTHER; Name: Chlorhexidine bathing; Assigned to Arm(s): Chlorhexidine bathing | Intervention Type: OTHER; Name: Non-chlorhexidine bathing; Assigned to Arm(s): Non-chlorhexidine bathing
B: Intervention Type: PROCEDURE; Name: Bathing with Chlorhexidine Impregnated Washcloths; Assigned to Arm(s): N/A
C: Arm Label: Chromogenic Arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Chromogenic surveillance | Arm Label: Molecular Arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Molecular surveillance | Intervention Type: OTHER; Name: Chromogenic surveillance; Assigned to Arm(s): Chromogenic Arm | Intervention Type: OTHER; Name: Molecular surveillance; Assigned to Arm(s): Molecular Arm
D: Intervention Type: PROCEDURE; Name: Reinforced isolation + Muciprocine; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Effect of Oral Immune-Enhancing Nutritional Supplement on Hepatic Function After Liver Resection for Primary or Secondary Cancer on Cirrhosis or Liver Fibrosis
Brief Summary: Cirrhotic patients undergoing hepatic resection have a mortality rate near 10%, and 30 to 70% of them develop severe complications. These failures are mainly due to hepatic insufficiency. Studies have already shown benefits of oral nutritional supplements in ORL, digestive, and cardiac surgery. We aimed to ascertain whether this nutritional, immune-enhancing supplementation, administered 7 days before and 3 days after surgery, could improve liver function and postoperative host defences in patients with liver cancer resection.


Options:
A: Arm Label: Aminolaban EN; Type: EXPERIMENTAL; Interventions: Drug: Aminoleban EN | Arm Label: Control; Type: NO_INTERVENTION; Interventions: Drug: Aminoleban EN | Intervention Type: DRUG; Name: Aminoleban EN; Assigned to Arm(s): Aminolaban EN, Control
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Oral Impact® | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Oral Impact®; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard ERAS group | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Post operative laxation (Magnesium Oxide) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Preoperative metabolic conditioning postoperative nutritional supplementation | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Post operative laxation (Magnesium Oxide), Dietary Supplement: Preoperative metabolic conditioning postoperative nutritional supplementation | Intervention Type: DRUG; Name: Post operative laxation (Magnesium Oxide); Assigned to Arm(s): 2, 4 | Intervention Type: DIETARY_SUPPLEMENT; Name: Preoperative metabolic conditioning postoperative nutritional supplementation; Assigned to Arm(s): 3, 4 | Intervention Type: OTHER; Name: Standard ERAS group; Assigned to Arm(s): 1
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Immunonutrition | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: food for special medical purposes (FSMP) | Intervention Type: DIETARY_SUPPLEMENT; Name: Immunonutrition; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: food for special medical purposes (FSMP); Assigned to Arm(s): 2

Answer: B